200 related articles for article (PubMed ID: 19962759)
1. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Karp JE; Blackford A; Smith BD; Alino K; Seung AH; Bolaños-Meade J; Greer JM; Carraway HE; Gore SD; Jones RJ; Levis MJ; McDevitt MA; Doyle LA; Wright JJ
Leuk Res; 2010 Jul; 34(7):877-82. PubMed ID: 19962759
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Karp JE; Garrett-Mayer E; Estey EH; Rudek MA; Smith BD; Greer JM; Drye DM; Mackey K; Dorcy KS; Gore SD; Levis MJ; McDevitt MA; Carraway HE; Pratz KW; Gladstone DE; Showel MM; Othus M; Doyle LA; Wright JJ; Pagel JM
Haematologica; 2012 Nov; 97(11):1736-42. PubMed ID: 22733022
[TBL] [Abstract][Full Text] [Related]
3. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Karp JE; Smith BD; Levis MJ; Gore SD; Greer J; Hattenburg C; Briel J; Jones RJ; Wright JJ; Colevas AD
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4467-73. PubMed ID: 17671131
[TBL] [Abstract][Full Text] [Related]
4. Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next?
van der Jagt RH
Leuk Res; 2010 Jul; 34(7):856-7. PubMed ID: 20378170
[No Abstract] [Full Text] [Related]
5. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
Zeidner JF; Foster MC; Blackford AL; Litzow MR; Morris LE; Strickland SA; Lancet JE; Bose P; Levy MY; Tibes R; Gojo I; Gocke CD; Rosner GL; Little RF; Wright JJ; Doyle LA; Smith BD; Karp JE
Haematologica; 2015 Sep; 100(9):1172-9. PubMed ID: 26022709
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Litzow MR; Wang XV; Carroll MP; Karp JE; Ketterling RP; Zhang Y; Kaufmann SH; Lazarus HM; Luger SM; Paietta EM; Pratz KW; Tun HW; Altman JK; Broun ER; Rybka WB; Rowe JM; Tallman MS
Am J Hematol; 2019 Jan; 94(1):111-117. PubMed ID: 30370956
[TBL] [Abstract][Full Text] [Related]
7. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.
Archimbaud E; Leblond V; Michallet M; Cordonnier C; Fenaux P; Travade P; Dreyfus F; Jaubert J; Devaux Y; Fiere D
Blood; 1991 May; 77(9):1894-900. PubMed ID: 2018832
[TBL] [Abstract][Full Text] [Related]
8. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.
Karp JE; Smith BD; Resar LS; Greer JM; Blackford A; Zhao M; Moton-Nelson D; Alino K; Levis MJ; Gore SD; Joseph B; Carraway H; McDevitt MA; Bagain L; Mackey K; Briel J; Doyle LA; Wright JJ; Rudek MA
Blood; 2011 Mar; 117(12):3302-10. PubMed ID: 21239698
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G
Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
Bolaños-Meade J; Guo C; Gojo I; Karp JE
Leuk Res; 2004 Jun; 28(6):571-7. PubMed ID: 15120933
[TBL] [Abstract][Full Text] [Related]
13. Intensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone.
Liang R; Chan TK; Chu YC; Chan J; Chan CH; Chiu E; Lie A; Kwong YL; Yeung YM; Chan LC
Anticancer Drugs; 1995 Apr; 6(2):224-8. PubMed ID: 7795271
[TBL] [Abstract][Full Text] [Related]
14. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience.
Vignetti M; Orsini E; Petti MC; Moleti ML; Andrizzi C; Pinto RM; Amadori S; Meloni G
Ann Oncol; 1996 Nov; 7(9):933-8. PubMed ID: 9006744
[TBL] [Abstract][Full Text] [Related]
15. Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.
Zeidner JF; Lee DJ; Frattini M; Fine GD; Costas J; Kolibaba K; Anthony SP; Bearss D; Smith BD
Clin Cancer Res; 2021 Jan; 27(1):60-69. PubMed ID: 32998965
[TBL] [Abstract][Full Text] [Related]
16. Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).
Zeidner JF; Foster MC; Blackford AL; Litzow MR; Morris LE; Strickland SA; Lancet JE; Bose P; Levy MY; Tibes R; Gojo I; Gocke CD; Rosner GL; Little RF; Wright JJ; Doyle LA; Smith BD; Karp JE
Leuk Res; 2018 Sep; 72():92-95. PubMed ID: 30118897
[No Abstract] [Full Text] [Related]
17. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.
Archimbaud E; Thomas X; Leblond V; Michallet M; Fenaux P; Cordonnier C; Dreyfus F; Troussard X; Jaubert J; Travade P
J Clin Oncol; 1995 Jan; 13(1):11-8. PubMed ID: 7799010
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
Giebel S; Krawczyk-Kulis M; Adamczyk-Cioch M; Jakubas B; Palynyczko G; Lewandowski K; Dmoszynska A; Skotnicki A; Nowak K; Holowiecki J;
Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
[TBL] [Abstract][Full Text] [Related]
19. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients.
MacCallum PK; Rohatiner AZ; Davis CL; Whelan JS; Oza AM; Lim J; Love S; Amess JA; Leahy M; Gupta RK
Ann Hematol; 1995 Jul; 71(1):35-9. PubMed ID: 7632817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
